The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Targeting bromodomains: epigenetic readers of lysine acetylation
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Regulation of cellular metabolism by protein lysine acetylation
Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., Yao, J., Zhou, L., Zeng, Y., Li, H., et al. (2010) · Science · doi:10.1126/science.1179689 · Cited by 1,910
Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions
Shogren-Knaak, M., Ishii, H., Sun, J.-M., Pazin, M. J., Davie, J. R., & Peterson, C. L. (2006) · Science · doi:10.1126/science.1124000 · Cited by 1,873
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Structure and ligand of a histone acetyltransferase bromodomain
Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
Self-citationSuppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479
Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291
Acetylation: a regulatory modification to rival phosphorylation?
Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1176 · Cited by 1,160
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110
The Inheritance of Epigenetic Defects
Holliday, R. (1987) · Science · doi:10.1126/science.3310230 · Cited by 1,082
Tamkun, J. W., Deuring, R., Scott, M. P., Kissinger, M., Pattatucci, A. M., Kaufman, T. C., & Kennison, J. A. (1992) · Cell · doi:10.1016/0092-8674(92)90191-e · Cited by 971
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09730 · Cited by 949
Retinoblastoma protein represses transcription by recruiting a histone deacetylase
Magnaghi-Jaulin, L., Groisman, R., Naguibneva, I., Robin, P., Lorain, S., Le Villain, J. P., Troalen, F., Trouche, D., & Harel-Bellan, A. (1998) · Nature · doi:10.1038/35410 · Cited by 909
The Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
Structure and Function of a Human TAF II 250 Double Bromodomain Module
Jacobson, R. H., Ladurner, A. G., King, D. S., & Tjian, R. (2000) · Science · doi:10.1126/science.288.5470.1422 · Cited by 843
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735
Interchromosomal associations between alternatively expressed loci
Spilianakis, C. G., Lalioti, M. D., Town, T., Lee, G. R., & Flavell, R. A. (2005) · Nature · doi:10.1038/nature03574 · Cited by 730
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation
Wu, S.-Y., & Chiang, C.-M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700001200 · Cited by 679
Control of Inducible Gene Expression by Signal-Dependent Transcriptional Elongation
Hargreaves, D. C., Horng, T., & Medzhitov, R. (2009) · Cell · doi:10.1016/j.cell.2009.05.047 · Cited by 644
Iyer, N. G., Özdag, H., & Caldas, C. (2004) · Oncogene · doi:10.1038/sj.onc.1207118 · Cited by 638
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA
Huang, B., Yang, X.-D., Zhou, M.-M., Ozato, K., & Chen, L.-F. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01365-08 · Cited by 579
Owen, D. J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.22.6141 · Cited by 542
Regulation of tissue homeostasis by NF-κB signalling: implications for inflammatory diseases
Pasparakis, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2655 · Cited by 523
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Pérez‐Atayde, A. R., & Fletcher, J. A. (2003) · PubMed · Cited by 501
Midazolam and Other Benzodiazepines
Olkkola, K. T., & Ahonen, J. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-74806-9_16 · Cited by 488
Cooperative binding of two acetylation marks on a histone tail by a single bromodomain
Morinière, J., Rousseaux, S., Steuerwald, U., Soler-López, M., Curtet, S., Vitte, A.-L., Govin, J., Gaucher, J., Sadoul, K., Hart, D. J., et al. (2009) · Nature · doi:10.1038/nature08397 · Cited by 469
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310658110 · Cited by 468
Self-citationHistone deacetylases and cancer
Barneda-Zahonero, B., & Parra, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.003 · Cited by 446
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Self-citationBelkina, A. C., Nikolajczyk, B. S., & Denis, G. V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202838 · Cited by 418
Small-Molecule Inhibition of BRDT for Male Contraception
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J. E., Lemieux, M. E., Picaud, S., Yu, R. N., Qi, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.045 · Cited by 416
Self-citationBET Bromodomains Mediate Transcriptional Pause Release in Heart Failure
Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.013 · Cited by 406
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription
Bisgrove, D. A., Mahmoudi, T., Henklein, P., & Verdin, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705053104 · Cited by 387
Devaiah, B. N., Lewis, B. A., Cherman, N., Hewitt, M. C., Albrecht, B. K., Robey, P. G., Ozato, K., Sims, R. J., & Singer, D. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120422109 · Cited by 378
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., Rodig, S. J., Kung, A. L., Bradner, J. E., & Weinstock, D. M. (2012) · Blood · doi:10.1182/blood-2012-02-413021 · Cited by 374
The Mechanism of Transcriptional Synergy of an In Vitro Assembled Interferon-β Enhanceosome
Kim, T. K., & Maniatis, T. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80013-1 · Cited by 340
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Self-citationDiscovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
Chung, C.-W., Coste, H., White, J. H., Mirguet, O., Wilde, J., Gosmini, R. L., Delves, C., Magny, S. M., Woodward, R., Hughes, S. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200108t · Cited by 334
Hennekam, R. C. M. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201594 · Cited by 320
Mahdi, H., Fisher, B. A., Källberg, H., Plant, D., Malmström, V., Rönnelid, J., Charles, P., Ding, B., Alfredsson, L., Padyukov, L., et al. (2009) · Nature Genetics · doi:10.1038/ng.480 · Cited by 308
Mirguet, O., Gosmini, R., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M., Mordaunt, J. E., Grimes, R. M., Crowe, M., Pineau, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401088k · Cited by 305
Li, Z., Guo, J., Wu, Y., & Zhou, Q. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks976 · Cited by 301
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L. A., Thompson, R. C., Muller, S., Knapp, S., & Wang, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3066 · Cited by 299
Self-citationCelic, I., Masumoto, H., Griffith, W. P., Meluh, P., Cotter, R. J., Boeke, J. D., & Verreault, A. (2006) · Current Biology · doi:10.1016/j.cub.2006.06.023 · Cited by 291
The BRG1 transcriptional coregulator
Trotter, K. W., & Archer, T. K. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06004 · Cited by 287
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Vidler, L. R., Brown, N., Knapp, S., & Hoelder, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300346w · Cited by 278
Self-citationXue, Y., Canman, J. C., Lee, C. S., Nie, Z., Yang, D., Moreno, G. T., Young, M. K., Salmon, E. D., & Wang, W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240208597 · Cited by 267
Pathogenesis of NUT Midline Carcinoma
French, C. A. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132438 · Cited by 264
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., Nair, S., & Chen, L.-F. (2014) · Oncogene · doi:10.1038/onc.2013.179 · Cited by 259
Bromodomain‐dependent stage‐specific male genome programming by Brdt
Gaucher, J., Boussouar, F., Montellier, E., Curtet, S., Buchou, T., Bertrand, S., Hery, P., Jounier, S., Depaux, A., Vitte, A., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.233 · Cited by 253
PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M. E., Owen, D. R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3292 · Cited by 249
Self-citationRational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer
Thurn, K. T., Thomas, S., Moore, A., & Munster, P. N. (2011) · Future Oncology · doi:10.2217/fon.11.2 · Cited by 246
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Segura, M. F., Fontanals-Cirera, B., Gaziel-Sovran, A., Guijarro, M. V., Hanniford, D., Zhang, G., González-Gomez, P., Morante, M., Jubierre, L., Zhang, W., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0122-t · Cited by 239
Lamonica, J. M., Deng, W., Kadauke, S., Campbell, A. E., Gamsjaeger, R., Wang, H., Cheng, Y., Billin, A. N., Hardison, R. C., Mackay, J. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102140108 · Cited by 238
Mammalian ASH1L Is a Histone Methyltransferase That Occupies the Transcribed Region of Active Genes
Gregory, G. D., Vakoc, C. R., Rozovskaia, T., Zheng, X., Patel, S., Nakamura, T., Canaani, E., & Blobel, G. A. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00993-07 · Cited by 237
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
Boehm, D., Calvanese, V., Dar, R. D., Xing, S., Schroeder, S., Martins, L., Aull, K., Li, P.-C., Planelles, V., Bradner, J. E., et al. (2013) · Cell Cycle · doi:10.4161/cc.23309 · Cited by 235
Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 234
Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines
Lange, B., Valtieri, M., Santoli, D., Caracciolo, D., Mavilio, F., Gemperlein, I., Griffin, C., Emanuel, B., Finan, J., & Nowell, P. (1987) · Blood · doi:10.1182/blood.v70.1.192.192 · Cited by 232
BET bromodomain inhibition suppresses TH17-mediated pathology
Mele, D. A., Salmeron, A., Ghosh, S., Huang, H.-R., Bryant, B. M., & Lora, J. M. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130376 · Cited by 229
The multi-tasking P-TEFb complex
Brès, V., Yoh, S. M., & Jones, K. A. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.04.008 · Cited by 229
Ember, S. W. J., Zhu, J.-Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., & Schönbrunn, E. (2014) · ACS Chemical Biology · doi:10.1021/cb500072z · Cited by 221
Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming
Schwartz, B. E., Hofer, M. D., Lemieux, M. E., Bauer, D. E., Cameron, M. J., West, N. H., Agoston, E. S., Reynoird, N., Khochbin, S., Ince, T. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3513 · Cited by 217
3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
Hewings, D. S., Wang, M., Philpott, M., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200640v · Cited by 216
Self-citationBuurman, R., Gürlevik, E., Schäffer, V., Eilers, M., Sandbothe, M., Kreipe, H., Wilkens, L., Schlegelberger, B., Kühnel, F., & Skawran, B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.033 · Cited by 211
Seal, J., Lamotte, Y., Donche, F., Bouillot, A., Mirguet, O., Gellibert, F., Nicodeme, E., Krysa, G., Kirilovsky, J., Beinke, S., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.041 · Cited by 209
Wyce, A., Ganji, G., Smitheman, K. N., Chung, C.-W., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P. D., McCabe, M. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072967 · Cited by 206
Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia
Nebral, K., Denk, D., Attarbaschi, A., König, M., Mann, G., Haas, O. A., & Strehl, S. (2009) · Leukemia · doi:10.1038/leu.2008.306 · Cited by 204
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Chaidos, A., Caputo, V., Gouvedenou, K., Liu, B., Marigo, I., Chaudhry, M. S., Rotolo, A., Tough, D. F., Smithers, N. N., Bassil, A. K., et al. (2014) · Blood · doi:10.1182/blood-2013-01-478420 · Cited by 203
Zhang, G., Liu, R., Zhong, Y., Plotnikov, A. N., Zhang, W., Zeng, L., Rusinova, E., Gerona-Nevarro, G., Moshkina, N., Joshua, J., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.359505 · Cited by 201
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
McLure, K. G., Gesner, E. M., Tsujikawa, L., Kharenko, O. A., Attwell, S., Campeau, E., Wasiak, S., Stein, A., White, A., Fontano, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083190 · Cited by 198
Fish, P. V., Filippakopoulos, P., Bish, G., Brennan, P. E., Bunnage, M. E., Cook, A. S., Federov, O., Gerstenberger, B. S., Jones, H., Knapp, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010515 · Cited by 198
Self-citationPlace your BETs: the therapeutic potential of bromodomains
Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197
BET proteins promote efficient murine leukemia virus integration at transcription start sites
Sharma, A., Larue, R. C., Plumb, M. R., Malani, N., Male, F., Slaughter, A., Kessl, J. J., Shkriabai, N., Coward, E., Aiyer, S. S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307157110 · Cited by 193
Atack, J. R. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.5.601 · Cited by 192
Fiskus, W., Sharma, S., Qi, J., Valenta, J. A., Schaub, L. J., Shah, B., Peth, K., Portier, B. P., Rodriguez, M., Devaraj, S. G. T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0770 · Cited by 190
Chung, C.-W., Dean, A. W., Woolven, J. M., & Bamborough, P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201320w · Cited by 188
Reynoird, N., Schwartz, B. E., Delvecchio, M., Sadoul, K., Meyers, D., Mukherjee, C., Caron, C., Kimura, H., Rousseaux, S., Cole, P. A., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.176 · Cited by 188
Brd2 disruption in mice causes severe obesity without Type 2 diabetes
Wang, F., Liu, H., Blanton, W. P., Belkina, A., Lebrasseur, N. K., & Denis, G. V. (2010) · Biochemical Journal · doi:10.1042/bj20090928 · Cited by 185
Karn, J. (2011) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328340ffbb · Cited by 184
Bandukwala, H. S., Gagnon, J., Togher, S., Greenbaum, J. A., Lamperti, E. D., Parr, N. J., Molesworth, A. M. H., Smithers, N., Lee, K., Witherington, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212264109 · Cited by 181
Zhang, W., Prakash, C., Sum, C., Gong, Y., Li, Y., Kwok, J. J. T., Thiessen, N., Pettersson, S., Jones, S. J. M., Knapp, S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.413047 · Cited by 181
Self-citationQUIRK, K., BLURTON, P., FLETCHER, S., LEESON, P., TANG, F., MELLILO, D., RAGAN, C. I., & MCKERNAN, R. M. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00061-5 · Cited by 180
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Wyce, A., Degenhardt, Y., Bai, Y., Le, B., Korenchuk, S., Crouthamel, M.-C., McHugh, C. F., Vessella, R., Creasy, C. L., Tummino, P. J., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1572 · Cited by 179
Bamborough, P., Diallo, H., Goodacre, J. D., Gordon, L., Lewis, A., Seal, J. T., Wilson, D. M., Woodrow, M. D., & Chung, C.-W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201283q · Cited by 175
TIF1γ, a novel member of the transcriptional intermediary factor 1 family
Venturini, L., You, J., Stadler, M., Galien, R., Lallemand, V., Koken, M. H., Mattei, M. G., Ganser, A., Chambon, P., Losson, R., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202655 · Cited by 170
Roderick, J. E., Tesell, J., Shultz, L. D., Brehm, M. A., Greiner, D. L., Harris, M. H., Silverman, L. B., Sallan, S. E., Gutiérrez, A., Look, A. T., et al. (2014) · Blood · doi:10.1182/blood-2013-08-522698 · Cited by 160
Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association
Zeng, L., Li, J., Muller, M., Yan, S., Mujtaba, S., Pan, C., Wang, Z., & Zhou, M.-M. (2005) · Journal of the American Chemical Society · doi:10.1021/ja044885g · Cited by 160
Herrmann, H., Blatt, K., Shi, J., Gleixner, K. V., Cerny‐Reiterer, S., Müllauer, L., Vakoc, C. R., Sperr, W. R., Horny, H., Bradner, J. E., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.733 · Cited by 160
The WSTF-SNF2h Chromatin Remodeling Complex Interacts with Several Nuclear Proteins in Transcription
Cavellán, E., Asp, P., Percipalle, P., & Farrants, A. Ö. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600233200 · Cited by 159
Martin, M. P., Olesen, S. H., Georg, G. I., & Schönbrunn, E. (2013) · ACS Chemical Biology · doi:10.1021/cb4003283 · Cited by 158
Verster, J. C., & Volkerts, E. R. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00003.x · Cited by 157
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
Henssen, A. G., Thor, T., Odersky, A., Heukamp, L. C., Hindy, N. E., Beckers, A., Speleman, F., Althoff, K., Schäfers, S., Schramm, A. R., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1534 · Cited by 151
BET bromodomain proteins are required for glioblastoma cell proliferation
Pastori, C., Daniel, M. L., Penas, C., Volmar, C., Johnstone, A. L., Brothers, S. P., Graham, R. M., Allen, B. K., Sarkaria, J. N., Komotar, R. J., et al. (2014) · Epigenetics · doi:10.4161/epi.27906 · Cited by 149
Sachchidanand, Resnick‐Silverman, L., Yan, S. X., Mutjaba, S., Liu, W., Zeng, L., Manfredi, J. J., & Zhou, M. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.10.014 · Cited by 145
Activation of chromatin by acetylation of histone side chains.
Marushige, K. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.3937 · Cited by 143
Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands
Hewings, D. S., Fedorov, O., Filippakopoulos, P., Martin, S., Picaud, S., Tumber, A., Wells, C. D., Olcina, M. M., Freeman, K. M., Gill, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301588r · Cited by 141
Self-citationGupta, S. S., Maetzig, T., Maertens, G. N., Sharif, A., Rothe, M., Weidner-Glunde, M., Galla, M., Schambach, A., Cherepanov, P., & Schulz, T. F. (2013) · Journal of Virology · doi:10.1128/jvi.01942-13 · Cited by 139
Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
Zhang, G., Plotnikov, A. N., Rusinova, E. V., Shen, T., Morohashi, K., Joshua, J., Zeng, L., Mujtaba, S., Ohlmeyer, M. H. J., & Zhou, M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401334s · Cited by 137
Real-time imaging of histone H4 hyperacetylation in living cells
Sasaki, K., Ito, T., Nishino, N., Khochbin, S., & Yoshida, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902150106 · Cited by 137
A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes
Borah, J. C., Mujtaba, S., Karakikes, I., Zeng, L., Müller, M., Patel, J. A., Moshkina, N., Morohashi, K., Zhang, W., Gerona‐Navarro, G., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.021 · Cited by 136
Filippakopoulos, P., Picaud, S., Fedorov, O., Keller, M., Wrobel, M. N., Morgenstern, O., Bracher, F., & Knapp, S. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.080 · Cited by 133
Self-citationDiscovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Vidler, L. R., Filippakopoulos, P., Fedorov, O., Picaud, S., Martin, S., Tomsett, M., Woodward, H. L., Brown, N., Knapp, S., & Hoelder, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011302 · Cited by 131
Self-citationCamós, M., Esteve, J., Jares, P., Colomer, D., Rozman, M., Villamor, N., Costa, D., Carrió, A., Nomdedeu, J. F., Montserrat, E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4601 · Cited by 129
Gamsjaeger, R., Webb, S. R., Lamonica, J. M., Billin, A. N., Blobel, G. A., & Mackay, J. P. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05413-11 · Cited by 128
Zhao, L., Cao, D., Chen, T., Wang, Y.-Q., Miao, Z., Xu, Y., Chen, W., Wang, X., Li, Y., Du, Z., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301793a · Cited by 123
The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
Dittmann, A., Werner, T., Chung, C., Savitski, M. M., Savitski, M. F., Grandi, P., Hopf, C., Lindon, M. J., Neubauer, G., Prinjha, R. K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400789e · Cited by 120
From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151
Mirguet, O., Lamotte, Y., Donche, F., Toum, J., Gellibert, F. J., Bouillot, A., Gosmini, R. L., Nguyen, V.-L., Delannée, D., Seal, J. T., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.125 · Cited by 115
4‐Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading
Lucas, X., Wohlwend, D., Hügle, M. J., Schmidtkunz, K., Gerhardt, S., Schüle, R., Jung, M., Einsle, O., & Günther, S. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307652 · Cited by 113
Mechanisms of Resistance to Histone Deacetylase Inhibitors
Lee, J., Choy, M. L., & Marks, P. A. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00002-1 · Cited by 110
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors
Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Leblanc, Y., Côté, A., Nasveschuk, C. G., Taylor, A. M., Harmange, J.-C., Audia, J. E., Pardo, E., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4001485 · Cited by 107
Ito, T., Umehara, T., Sasaki, K., Nakamura, Y., Nishino, N., Terada, T., Shirouzu, M., Padmanabhan, B., Yokoyama, S., Ito, A., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.02.009 · Cited by 103
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
Tolani, B., Ramakrishnan, G., Punj, V., Matta, H., & Chaudhary, P. M. (2013) · Oncogene · doi:10.1038/onc.2013.242 · Cited by 103
Ferguson, F. M., Fedorov, O., Chaikuad, A., Philpott, M., Muniz, J. R. C., Felletár, I., von Delft, F., Heightman, T. D., Knapp, S., Abell, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401582c · Cited by 101
Self-citation[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains
Fedorov, O., Lingard, H., Wells, C. D., Monteiro, O., Picaud, S., Keates, T., Yapp, C., Philpott, M., Martin, S. J., Felletár, I., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401568s · Cited by 99
Self-citationRoscioli, T., Cliffe, S. T., Bloch, D. B., Bell, C. G., Mullan, G. L., Taylor, P. J., Sarris, M., Wang, J., Donald, J. A., Kirk, E. P., et al. (2006) · Nature Genetics · doi:10.1038/ng1780 · Cited by 98
ChromoHub: a data hub for navigators of chromatin-mediated signalling
Liu, L., Zhen, X. T., Denton, E., Marsden, B. D., & Schapira, M. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts340 · Cited by 96
HDAC inhibitors overcome first hurdle
Garber, K. (2007) · Nature Biotechnology · doi:10.1038/nbt0107-17 · Cited by 94
Nicholls, S. J., Gordon, A., Johannson, J., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Wong, N. C. W., Borgman, M., & Nissen, S. E. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6373-5 · Cited by 93
Helen, S., Horne, G. A., Bastow, S., & Chevassut, T. J. T. (2013) · Cancer Medicine · doi:10.1002/cam4.146 · Cited by 91
Bromodomain Protein Brd4 Plays a Key Role in Merkel Cell Polyomavirus DNA Replication
Wang, X., Li, J., Schowalter, R. M., Jiao, J., Buck, C. B., & You, J. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003021 · Cited by 91
GABAA-receptor Subtypes: Clinical Efficacy and Selectivity of Benzodiazepine Site Ligands
Korpi, E. R., Mattila, M. J., Wisden, W., & Lüddens, H. (1997) · Annals of Medicine · doi:10.3109/07853899708999348 · Cited by 91
Emadali, A., Rousseaux, S., Costa, J. B., Rome, C., Duley, S., Hamaidia, S., Betton-Fraisse, P., Debernardi, A., Leroux, D., Bernay, B., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202034 · Cited by 89
Costa, D. D., Agathanggelou, A., Perry, T., Weston, V., Petermann, E., Zlatanou, A., Oldreive, C., Wei, W., Stewart, G. S., Longman, J., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.24 · Cited by 88
Self-citationWang, X., Helfer, C. M., Pancholi, N. J., Bradner, J. E., & You, J. (2013) · Journal of Virology · doi:10.1128/jvi.03068-12 · Cited by 86
Berkovits, B. D., & Wolgemuth, D. J. (2011) · Developmental Biology · doi:10.1016/j.ydbio.2011.10.005 · Cited by 74
BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms
Wyspianska, B. S., Bannister, A. J., Barbieri, I., Nangalia, J., Godfrey, A. L., Calero‐Nieto, F. J., Robson, S. C., Rioja, I., Li, J., Wiese, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.234 · Cited by 73
Katsumoto, T., Yoshida, N., & Kitabayashi, I. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00865.x · Cited by 72
Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human
Malik, S., & Bhaumik, S. R. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07607.x · Cited by 71
Wienerroither, S., Rauch, I., Rosebrock, F., Jamieson, A. M., Bradner, J. E., Muhar, M., Zuber, J. A., Müller, M. M., & Decker, T. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01353-13 · Cited by 70
Hay, D. A., Fedorov, O., Filippakopoulos, P., Martin, S., Philpott, M., Picaud, S., Hewings, D. S., Uttakar, S., Heightman, T. D., Conway, S. J., et al. (2012) · MedChemComm · doi:10.1039/c2md20189e · Cited by 68
Self-citationLiu, S., Walker, S. R., Nelson, E. A., Cerulli, R. A., Xiang, M. H., Toniolo, P. A., Qi, J., Stone, R. M., Wadleigh, M., Bradner, J. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0341 · Cited by 67
Yan, J., Li, Q., Lievens, S., Tavernier, J. H., & You, J. (2009) · Journal of Virology · doi:10.1128/jvi.01647-09 · Cited by 67
Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia
Nebral, K., Denk, D., Attarbaschi, A., König, M., Mann, G., Haas, O., & Strehl, S. (2009) · Klinische Pädiatrie · doi:10.1055/s-0029-1222663 · Cited by 65
Management of Prolonged Seizures and Status Epilepticus in Childhood: A Systematic Review
Sofou, K., Kristjánsdóttir, R., Papachatzakis, N. E., Ahmadzadeh, A., & Uvebrant, P. (2009) · Journal of Child Neurology · doi:10.1177/0883073809332768 · Cited by 64
Casula, M. A., Bromidge, F. A., Pillai, G. V., Wingrove, P. B., Martin, K., Maubach, K. A., Seabrook, G. R., Whiting, P. J., & Hadingham, K. L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00289.x · Cited by 61
Tsume-Kajioka, M., Kimura-Yoshida, C., Mochida, K., Shibukawa, Y., Amazaki, S., Wada, Y., Hiramatsu, R., Shimokawa, K., & Matsuo, I. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.149 · Cited by 48
Naphthyridines as Novel BET Family Bromodomain Inhibitors
Mirguet, O., Lamotte, Y., Chung, C., Bamborough, P., Delannée, D., Bouillot, A., Gellibert, F. J., Krysa, G., Lewis, A. J., Witherington, J. J., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300259 · Cited by 35
Dubnick, B., LIPPA, A. S., Klepner, C. A., Coupet, J., Greenblatt, E., & Beer, B. (1983) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(83)90385-4 · Cited by 35
HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer
McConkey, D. J., White, M. C., & Yan, W. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00004-5 · Cited by 35
Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16)
Zhang, Y., Zeleznik‐Le, N. J., Emmanuel, N., Jayathilaka, N., Chen, J., Strissel, P. L., Strick, R., Li, L. S., Neilly, M. B., Taki, T., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20077 · Cited by 28
Novel HDL-based therapeutic agents
JOY, T. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.004 · Cited by 26
Cullen, S. J., Ponnappan, S., & Ponnappan, U. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.09.008 · Cited by 23
Ohnishi, H., Taki, T., Yoshino, H., Takita, J., Ida, K., Ishii, M., Nishida, K., Hayashi, Y., Taniwaki, M., Bessho, F., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01154.x · Cited by 19
Kempen, H. J. M., Bellus, D., Fedorov, O., Nicklisch, S., Filippakopoulos, P., Picaud, S., & Knapp, S. (2013) · Lipid Insights · doi:10.4137/lpi.s13258 · Cited by 18
Self-citationFern�ndez, P., Guill�n, M. I., Úbeda, A., López-Cremades, P., Aller, E., Lorenzo, A., Molina, P., & Alcaraz, M. (2003) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0768-6 · Cited by 11
When are the BET factors the most sensitive to bromodomain inhibitors?
Khochbin, S. (2013) · Transcription · doi:10.4161/trns.23191 · Cited by 9
Cited by
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
Metadata
- Authors
- Filippakopoulos, P., & Knapp, S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-04-22
- Volume
- 13
- Issue
- 5
- Pages
- 337-356
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2003872705
- Cited by
- 1,243
- References
- 161
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.